Clinical trials: Myeloproliferative Disorders
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Studying Fentanyl in Patients With Cancer
RATIONALE: Studying blood samples from cancer patients undergoing pain treatment in the laboratory may help doctors learn more about how pain drugs work in the body.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00899951
- Testing
- fentanyl citrate, pharmacological study
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Myeloproliferative Disorders, Myeloproliferative Disorders (MPD)
Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry
The objective of this study is to better understand the underlying pathogenetic mechanisms of myeloproliferative disorders (MPDs).
- Trial name
- NCT01144780
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
Patients less than or equal to 21 years old with high-risk hematologic malignancies who would likely benefit from allogeneic hematopoietic cell transplantation (HCT).
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), NK-Cell Leukemia
- Trial name
- NCT03849651
- Testing
- Cyclophosphamide, Fludarabine, Thiotepa
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- St. Jude Children's Research Hospital
Philidelphia Positive Chronic Myeloid Leukaemia
Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
The purpose of this Australian study was to assess the efficacy and safety of nilotinib 300mg twice daily in patients with chronic myeloid leukemia chronic phase who were intolerant but responsive to 1st line treatment with…
- Trial name
- ENESTswift (NCT02108951)
- Testing
- Nilotinib
- Where
- 14 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase
Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt
The purpose of this observational study is to evaluate the effectiveness and safety of generic imatinib under usual clinical practice in patients of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) patients…
- Trial name
- NCT03454503
- Testing
- Imatinib
- Where
- Egypt
- Volunteers
- 173 people
- Sponsor
- Hikma Pharmaceuticals LLC
Leukemia, Myelodysplasia
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC)…
- Conditions
- Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT07249346
- Testing
- Ruxolitinib, Myeloablative conditioning regimen, Hematopoietic Stem Cell Transplantation
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Hannah Choe, MD
Chronic Myelogenous Leukemia
Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
The study was a local multicentric, open-label, non-randomized phase II study of nilotinib as a first line treatment in adult patients with newly-diagnosed Philadelphia chromosome-positive (Ph+) and chronic phase myeloid leukemia…
- Trial name
- NCT01274351
- Testing
- Nilotinib
- Where
- 13 sites in Turkey (Türkiye)
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
This phase II trial studies how well clofarabine and melphalan before a donor stem cell transplant works in treating patients with a decrease in or disappearance of signs and symptoms of myelodysplasia or acute leukemia (disease…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Myelodysplastic Syndrome
- Trial name
- NCT01885689
- Testing
- clofarabine, melphalan, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- City of Hope Medical Center
Acute Myelogenous Leukemia, Acute Lymphatic Leukemia
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT06680661
- Testing
- Cyclophosphamide, Fludarabine, Thiotepa
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Leland Metheny
Leukemia
PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy
RATIONALE: PHA-739358 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well PHA-739358 works in treating patients with chronic myelogenous…
- Trial name
- NCT00335868
- Testing
- danusertib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant.
- Conditions
- Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01199562
- Testing
- infection prophylaxis and management, laboratory biomarker analysis, flow cytometry
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- City of Hope Medical Center
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
This study will gather information about the combination the drugs plerixafor with sargramostim in donors of blood-forming cells (stem cells). These stem cells will be collected from the donor and transplanted into their sibling.
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Lymphoma, Non-Hodgkin, Hodgkin Disease
- Trial name
- NCT01158118
- Testing
- Sargramostim, Plerixafor
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Myeloproliferative Neoplasm
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
The purpose of the study is to evaluate the effectiveness and safety of fedratinib as maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic cell transplant (HCT).
- Trial name
- NCT05127174
- Testing
- Fedratinib Pill
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Chronic Myelogenous Leukemia, Multiple Myeloma
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation
Primary Objectives: To evaluate response rates of acute or chronic Graft-versus-host disease (GVHD) following CD8 depleted DLI (Depleted Donor Lymphocyte Infusions) in patients with Chronic myelomonocytic leukemia (CMML), chronic…
- Conditions
- Chronic Myelogenous Leukemia, Multiple Myeloma, Non Hodgkin's Lymphoma, Hodgkin's Disease
- Trial name
- NCT00038818
- Testing
- CD8 Depleted Donor Lymphocyte
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Myelofibrosis
A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vismodegib plus (+) ruxolitinib versus placebo + ruxolitinib in participants with intermediate- or high-risk MF.
- Trial name
- NCT02593760
- Testing
- Ruxolitinib, Vismodegib
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
RATIONALE: Belinostat and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving belinostat together with bortezomib may kill more cancer cells.
- Conditions
- Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
- Trial name
- NCT01075425
- Testing
- bortezomib, belinostat, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Virginia Commonwealth University
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
This phase II trial studies how well T cell depleted donor peripheral blood stem cell transplant works in preventing graft-versus-host disease in younger patients with high risk hematologic malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia
- Trial name
- NCT01858740
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Myeloproliferative Neoplasm
Remotely Administered Diet Intervention to Impact Symptom Burden in Myeloproliferative Neoplasm
Myeloproliferative Neoplasm (MPN) is a chronic blood cancer without cure. The major clinical issues in MPN are 1) an increased risk of blood clots 2) symptoms thought to be driven by chronic inflammation which in some cases can…
- Trial name
- NCT04744974
- Testing
- Diet intervention
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of California, Irvine
Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
- Trial name
- NCT03471260
- Testing
- Azacitidine, Ivosidenib, Venetoclax
- Where
- 4 sites in United States
- Volunteers
- 96 people
- Sponsor
- M.D. Anderson Cancer Center
Myelofibrosis
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib.
- Trial name
- NCT04485260
- Testing
- KRT-232, Ruxolitinib
- Where
- 38 sites in United States, Australia and 7 more
- Volunteers
- 36 people
- Sponsor
- Kartos Therapeutics, Inc.